Universal targeted drugs can reduce the risk of disease progression and death by 78%

Cabozantinib, a multi-target broad-spectrum anticancer drug, can inhibit multiple targets including MET, VEGFR2, RET, AXL, etc.

Recently, the American pharmaceutical company Exelixis published the latest clinical trial progress on Cabozantinib in The Lancet Oncology for the treatment of differentiated thyroid cancer (DTC), with the title "Cabozantinib for radioiodine-refractory differentiated thyroid.

https://doi.

Thyroid cancer has always been called "gentle cancer.

The clinical trial, named COSMIC-311, is a global, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial to evaluate the radioactivity of cabozantinib on previously received VEGFR targeted therapy Efficacy and safety of iodine-refractory DTC patients

187 patients from 164 clinics in 25 countries participated, randomly assigned to receive cabozantinib (n=125) or placebo (n=62) according to a 2:1 ratio.

The objective response rate of 100 randomly assigned patients and the progression-free survival rate of all randomly assigned patients before the trial were the primary endpoints.

Clinical trial data showed that in the interim analysis, the ITT population reached the primary endpoint of progression-free survival.

Comparison of the progression-free survival rate (A) and overall survival rate (B) between the cabozantinib group and the placebo group in the ITT population

In terms of safety, the rate of discontinuation in the cabozantinib group due to adverse events caused by treatment was 5%, and 71 subjects had grade 3 or 4 adverse events.

As early as February 2021, Cabozantinib has been granted breakthrough therapy designation by the US FDA for the treatment of radioactive iodine refractory differentiated thyroid cancer

Reference materials:

[1]https://#seccestitle10

[2]https://ir.